Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation
- PMID: 10876191
- DOI: 10.1067/msy.2000.107103
Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation
Abstract
Background: Multiple endocrine neoplasia type 2 (MEN 2) and familial medullary thyroid carcinoma (FMTC) are autosomal dominantly inherited cancer syndromes that predispose to C-cell hyperplasia and MTC. MEN 2A and FMTC are caused by mutations in the RET proto-oncogene.
Methods: We used a multiplex polymerase chain reaction-based assay to screen exons 10, 11, 13, and 14 of RET for mutations in 2 families with FMTC. We correlated mutation status with calcitonin and pathologic studies to determine genotype-phenotype correlations.
Results: We identified a mutation in codon 804 in exon 14 (GTG-->ATG; V804M) in both families. An 86-year-old person who was a gene carrier and other individuals over age 70 who were suspected by pedigree analysis to be gene carriers had no overt clinical evidence of MTC. Four of 21 patients who underwent a thyroidectomy also had papillary thyroid cancer. One individual in each family had metastatic MTC at age 30 and 32 years, and all 26 people having thyroidectomies had either MTC or C-cell hyperplasia, leading us to continue to recommend prophylactic thyroidectomy for all identified patients who were gene carriers.
Conclusions: Because of active MTC in younger members of these families, including metastases, we have continued to advocate thyroid surgery in mutation-positive individuals. While DNA diagnosis of gene carriers and subsequent genetic counseling was relatively straightforward, the acceptance of surgical recommendations was more difficult for some individuals. These families demonstrate that the search for RET mutations should include exons 13, 14, 15, and 16 in patients whose studies in exons 10 and 11 are negative.
Similar articles
-
Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.Surgery. 1995 Dec;118(6):1099-103; discussion 1103-4. doi: 10.1016/s0039-6060(05)80120-5. Surgery. 1995. PMID: 7491529
-
Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.Cancer. 2002 Jan 15;94(2):323-30. doi: 10.1002/cncr.10228. Cancer. 2002. PMID: 11900218
-
Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".Int J Cancer. 1996 Aug 22;69(4):312-6. doi: 10.1002/(SICI)1097-0215(19960822)69:4<312::AID-IJC13>3.0.CO;2-7. Int J Cancer. 1996. PMID: 8797874
-
RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.Horm Res. 1997;47(4-6):168-78. doi: 10.1159/000185461. Horm Res. 1997. PMID: 9167949 Review.
-
Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene.Langenbecks Arch Surg. 2003 Mar;388(1):17-26. doi: 10.1007/s00423-003-0368-4. Epub 2003 Mar 25. Langenbecks Arch Surg. 2003. PMID: 12690476 Review.
Cited by
-
Papillary thyroid carcinoma and multiple endocrine neoplasia type 2.J Endocrinol Invest. 2015 Nov;38(11):1233-7. doi: 10.1007/s40618-015-0290-y. Epub 2015 Apr 23. J Endocrinol Invest. 2015. PMID: 25903693
-
Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.Endocr Pathol. 2010 Jun;21(2):115-9. doi: 10.1007/s12022-010-9117-8. Endocr Pathol. 2010. PMID: 20369307
-
Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.Endocr Pathol. 2003 Spring;14(1):71-80. doi: 10.1385/ep:14:1:71. Endocr Pathol. 2003. PMID: 12746565
-
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.Endocr Relat Cancer. 2015 Feb;22(1):65-76. doi: 10.1530/ERC-14-0491. Epub 2014 Nov 25. Endocr Relat Cancer. 2015. PMID: 25425582 Free PMC article.
-
Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET.Am J Med Genet A. 2021 Apr;185(4):1282-1287. doi: 10.1002/ajmg.a.62099. Epub 2021 Feb 21. Am J Med Genet A. 2021. PMID: 33615670 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases